2023 年 259 巻 2 号 p. 173-174
In the version of this article published in the February issue, 2021, the author mistook the affiliation of the first author. The correct affiliation of Toyotaka Kasai is Department of Gastroenterology, Fukaya Red Cross Hospital, Fukaya, Saitama, Japan and Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Concerning the “Table 1” (Page 91) of this article, the authors found that the sex item was missing. Table 1 added sex item is the next page. The authors sincerely apologize for the oversight on this matter.
Relationship between patient factors and the success or failure of vonoprazan-based second-line therapy for Hp eradication.
The chi-square test was used for categorical variables. The presence of Helicobacter pylori-related diseases was defined as having a history of gastric ulcers, duodenal ulcers, or ER for gastric neoplasia. The success rate of vonoprazan-based second-line therapy was greater in the high-BMI patient group (≥ 23.8 kg/m2) than in the low-BMI patient group (< 23.8 kg/m2; p = 0.007). No correlations were observed between eradication success and other patient factors, including the metronidazole/amoxicillin MICs.
BMI, body mass index; ER, endoscopic resection; Hp, Helicobacter pylori; MIC, minimal inhibitory concentration; PPI, proton pump inhibitor; SD, standard deviation; vonoprazan-based second-line therapy, vonoprazan with amoxicillin and metronidazole therapy.
